NCT Number: NCT02900040
Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation
The French DIVAT (standing for Données Informatisées et VAlidées en Transplantation in french, and in English "Computerized and VAlidated Data in Transplantation" ) cohort was Kicked off in 1994 by the Transplantation Urology Nephrology Institute of the Nantes University Hospital in France. The primary objective of this multicenter computerized database was to enable prospective clinical and epidemiological research studies concerning kidney transplant recipients, particularly focusing on mid- and long-term clinical outcomes, therapeutic strategies and public health issues. The patient-case system of the DIVAT cohort allows the monitoring of medical records of all patient-specific and allograft-specific data, including bio-banking since 2005. Data are collected from the date of transplantation until the graft failure, at each scheduled outpatient visit or hospital admission motivating by a new clinical, therapeutical or biological expression. The DIVAT cohort contains information on more than 11000 transplant recipients between 1994 and today, issued from 8 French university hospitals centers (the DIVAT Network is organized by a consortium agreement). 18% of all patients underwent retransplantation and 11% of all kidney transplants originated from living donors. The DIVAT network heavily works to ensure a high-quality data collection with the aim of exploring adequately the complex post-transplantation process. The Divat network encourage collaborations and enables interested researchers to submit a research project by completing a request form available on the DIVAT website (http://www.divat.fr/en) describing the context, objectives and design of the study
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Docteur Buron, Lyon, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- over the age of 18 years
- with renal transplant
Exclusion criteria
- minor
- pediatric transplantation
Treatment and study plan
Primary outcomes
-
Proportion of participants with Overall Survival
Time frame: 2 years
-
Proportion of participants with Overall Survival
Time frame: 4 years
-
Proportion of participants with Overall Survival
Time frame: 6 years
Secondary outcomes
-
expansion of effector memory CD8+ T cells dosage
Time frame: 1 year
potential marker for acute graft dysfunction
-
expansion of effector memory CD8+ T cells dosage
Time frame: 6 years
potential marker for late graft dysfunction
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Nantes University Hospital
Other
Registry information
Official study title
The French DIVAT: a Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation
Acronym: DIVAT
Important dates
- Study start
- 1994
- Primary completion
- 2050
- Study completion
- 2050
- First posted
- Sep 14, 2016
- Registry last updated
- Sep 15, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647
AMR, Antibody-mediated Rejection
Birmingham, Alabama, United States
View Trial DetailsEvaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
NCT06824454
Hypophosphatemia, Kidney Transplantation
Stanford, California, United States
View Trial DetailsImmunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
NCT07607197
Alloimmunization, Chronic Disease
Barcelona, Catalonia, Spain
View Trial DetailsStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
NCT07224763
Chronic Disease, Disease Attributes
New York, United States
View Trial Details